News

Here are the latest TFRI news stories. See our archive for a full history of news.

  • August 26, 2015

    Terry Fox spent months in a pediatric ward for his bone cancer. Today, two of three Quebec researchers to receive funding from Terry Fox will pursue new ways to help children in hospital today who are battling a deadly form of leukemia. A third-funded researcher will test a recent molecular finding to see how the immune system might help kill prostate cancer tumour cells.

  • August 19, 2015

    Vancouver, BC --Terry Fox’s research legacy continues in British Columbia 35 years after he set out on his Marathon of Hope. Two local cancer researchers will use nearly $1-million in new research funding to explore ways to treat leukemia and diagnose lymphoma using novel, non-detrimental or invasive approaches involving vitamin C and simple blood tests.

  • August 19, 2015

    Guelph, Ontario - For the first time, funds raised for cancer research by the Terry Fox Foundation through the annual Terry Fox Run will be used to study osteosarcoma in dogs. Osteosarcoma is the form of bone cancer that took Terry Fox’s leg, and eventually his life in 1981. Dogs develop osteosarcoma at a rate 10 times higher than humans.

  • July 10, 2015

    Terry Fox-funded researchers are key members of a Canadian team to have launched the world’s first clinical trial of a new therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and could have fewer side effects than conventional chemotherapy and radiation.

  • April 23, 2015

    Ottawa, ON -- Terry Fox-funded researcher, Dr. Jean-Simon Diallo and his colleagues at the Ottawa Hospital Research Institute have discovered that compounds that disrupt our cells’ inner skeleton (called microtubule-destabilizing agents) can greatly enhance oncolytic virus cancer therapy in mouse and cell culture models.

  • April 22, 2015

    The Terry Fox Research Institute is pleased to announce the launch of its cancer research programs for 2015-2016 funded by the Terry Fox Foundation. Please check the Research section of the website for further details on competitions for The Terry Fox New Frontiers Program Project Grants, The Terry Fox New Investigator Awards and The Terry Fox Research Institute’s Translational Projects.

  • April 20, 2015

    Ottawa, ON -- Terry Fox funded researchers in Ottawa have found a way to make pancreatic cancer cells more vulnerable to cancer-killing viruses, known as oncolytic viruses. In a paper published today in Nature Medicine, the scientists describe how they can exploit the communication, or cross-talk, between pancreatic cancer and a specific cell type that supports the tumour.

  • April 13, 2015

    This weekend marked the 35th anniversary of the start of Terry Fox's Marathon of Hope, when he set off from St. John's NL on April 12, 1980. In the 35 years since that day over $650 million has been raised in Terry's name for cancer research. Terry's older brother, Fred Fox, has challenged the country to once again raise $1 for every Canadian as The Terry Fox Foundation hopes to raise $35 million this year. Read the full story on the CBC website.

  • March 05, 2015

    TFRI is saddened to hear of the death of Dr. Cy Frank, President and CEO of Alberta Innovates - Health Solutions, a TFRI partner.

    TFRI extends its condolences to Dr. Frank's family and friends and to the research community members in Alberta.

    Announcement from Alberta Innovates - Health Solutions

  • January 15, 2015

    The Terry Fox Research Institute congratulates Dr. John Bell and his team on their award of $25 million in funding from the Government of Canada's Networks of Centres of Excellence. Dr. Bell will launch Biotherapeutics for Cancer Treatment (BioCanRx), a new national initiative to move promising cancer biotherapeutics, such as cancer-killing viruses and immune cell therapies, from discovery to clinical trials.